UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~December~~February 153, ~~2016~~2017

DNIB UNWIND, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36072

56-2596148

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

c/o Development Specialists, Inc.

333 South Grand Avenue, Suite 4070

Los Angeles, California 90071

(Address of principal executive offices) (Zip Code)

(213) 617-2717

(Registrant’s telephone number, include area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.

Other Events.

AsQuarterly ~~previously disclosed, on October 11, 2016, the effective date (the “Effective Date”) of the plan of liquidation, as amended~~Summary ~~(the~~Report “Amended Plan”) of DNIB Unwind, Inc. (f/k/a BIND Therapeutics, Inc.) (the “Company”) and one of its subsidiaries (together, the “Debtors”) occurred and all assets of the Company were transferred to the DNIB Liquidating Trust, which is administered by Geoffrey L. Berman, who became the post-confirmation liquidating trustee (the “Liquidating Trustee”), as further described in the Amended Plan.

~~Also~~As as previously disclosed, on ~~November~~May 231, 2016, ~~the~~DNIB ~~Company~~Unwind, ~~filed~~Inc. (f/k/a ~~Notice~~BIND ofTherapeutics, ~~Distribution~~Inc.) (the “~~Notice~~Company”) and one of ~~Distribution”) with~~its subsidiaries filed voluntary petitions in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) ~~disclosing~~seeking ~~that~~relief under Chapter 11 of Title 11 of the ~~Liquidating~~United ~~Trustee~~States ~~intended~~Code. On toSeptember 26, ~~distribute~~2016, $8the ~~million~~Bankruptcy toCourt entered an order approving the ~~holders~~plan of ~~record~~liquidation atproposed by the ~~close~~Company and one of ~~business~~its onsubsidiaries ~~August 30~~(as amended, ~~2016~~ (the “~~Record Holders~~Plan”) ofand the ~~Company’s~~Liquidation ~~former~~Trust ~~common~~Agreement ~~stock~~by (and among the ~~“Initial~~Company, its ~~Equity~~debtor ~~Distribution”)~~subsidiary and Geoffrey L. Berman, ~~with~~solely ain ~~portion~~his capacity as trustee of the ~~Initial~~DNIB ~~Equity~~Liquidation ~~Distribution~~Trust to(the be“Liquidation ~~held~~Trust inAgreement”). ~~reserve~~As ~~pending~~previously ~~resolution~~disclosed, ofon October 11, 2016, the ~~Debtors’~~Plan ~~objection to~~went aeffective ~~proof~~and ofall ~~claim~~assets ~~filed~~of the byCompany ~~one~~were ~~former~~transferred ~~stockholder~~to (the ~~“Holdback”)~~DNIB Liquidation Trust.

On ~~December~~February 153, ~~2016~~2017, ~~consistent~~the ~~with~~Company ~~the~~filed ~~formerly~~its post-confirmation ~~disclosed~~quarterly ~~terms~~summary ofreport for the ~~Initial~~period ~~Equity~~of ~~Distribution~~October 1, 2016 through December 31, 2016 with the ~~Liquidating~~Bankruptcy ~~Trustee~~Court ~~distributed~~(the ~~$0.3811~~“Summary ~~per~~Report”), ~~share~~which toalso included, as required by the ~~Record~~Liquidation ~~Holders~~Trust Agreement, financial statements and receipts and disbursements of the ~~Company’s~~DNIB ~~former~~Liquidation ~~common~~Trust ~~stock~~for the fiscal year ended December 31, ~~other~~2016. ~~than~~The ~~with~~Summary ~~respect~~Report is attached to ~~those~~this ~~shares~~Current ~~subject~~Report toon ~~the~~Form ~~Holdback~~8-K as Exhibit 99.1.

~~SIGNATURES~~Cautionary Statements Regarding the Quarterly Summary Report

~~Pursuant~~The Company cautions holders of beneficial interests in the DNIB Liquidation Trust not to place undue reliance upon the information contained in the Summary Report. The Summary Report is limited in scope and has been prepared solely for the purpose of complying with requirements of the ~~Securities~~Bankruptcy ~~Exchange~~Court. ~~Act~~The ofSummary ~~1934~~Report was not reviewed by independent accountants, ~~the~~is ~~registrant~~in ~~has~~a ~~duly~~format ~~caused~~prescribed ~~this~~by ~~report~~applicable bankruptcy laws, and is subject to befuture adjustment. ~~signed~~The onfinancial ~~its~~information ~~behalf~~in the Summary Report was not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and, therefore, may exclude items required by GAAP, such as certain ~~the~~reclassifications, ~~undersigned~~non-cash ~~hereunto~~items, ~~duly~~accruals, ~~authorized~~valuations and disclosures.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits:


99.1		Post-Confirmation Quarterly Summary Report for the Period of October 1, 2016 through December 31, 2016, filed February 3, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	DNIB UNWIND, INC.

Date: February 8, 2017	By:	/s/ Geoffrey L. Berman

		Geoffrey L. Berman
		Chief Restructuring Officer

INDEX TO EXHIBITS


99.1		Post-Confirmation Quarterly Summary Report for the Period of October 1, 2016 through December 31, 2016, filed February 3, 2017

DNIB UNWIND, INC.

Date: December 21, 2016

/s/ Geoffrey L. Berman

Geoffrey L. Berman

Chief Restructuring Officer

Filing Compare · DNIB UNWIND, INC.